KOSDAQBiotech & Pharma009300

Sam-A Pharm

₩12,970▼ 0.08%2026-11-18 close
Market Cap
₩82.6B
Turnover
₩3,805,790
Volume
293 shares
Shares out.
6.4M
PER
6.5×
PBR
0.3×
EPS
₩1,977
Dividend Yield
6.19%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩800 per share · Prices as of the 2026-11-18 close

01

Report overview

Sam-A Pharm: Respiratory Dependence Remains the Test

Sam-A Pharm still relies heavily on respiratory products, and operating profit has declined for three consecutive quarters through the third quarter of 2026, so commercialization of its pipeline is the next checkpoint.

  1. 1

    Respiratory concentration: respiratory products were 65.4% of sales in the first-quarter 2026 quarterly report, and generic competition for the flagship Citus (pranlukast) has intensified according to press reports.

  2. 2

    Annual trend: sales peaked at KRW 97.2 billion in 2023 and fell for two consecutive years in 2024 and 2025, while 2025 operating profit dropped 55.1% to KRW 11 billion.

  3. 3

    Quarterly trend: after returning to operating profit of KRW 2.65 billion in the fourth quarter of 2025, operating profit declined for three consecutive quarters through the third quarter of 2026, which came in at KRW 610 million.

  4. 4

    Balance sheet and payouts: at the end of 2025, total equity was KRW 228.1 billion, all attributable to controlling shareholders, the debt ratio was 8.3%, and the 2025 payout ratio was 40.15%.

02

Business structure

Sam-A Pharm manufactures and sells pharmaceuticals, with product lines covering respiratory, antibiotic, dermatology, gastrointestinal, analgesic-antipyretic-anti-inflammatory and circulatory-endocrine drugs, plus OTC medicines and health functional foods.

In the first-quarter 2026 quarterly report, respiratory products were the largest line at 65.4%, followed by analgesic-antipyretic-anti-inflammatory at 15%, dermatology at 9.5%, gastrointestinal at 7.3% and antibiotics at 2.4%.

Key products include Citus, Codenal, Hebron, Setofen, Tantum, Neocetin, Peporin, Guard, Atok, Lidomex and Noma chewable tablets.

Citus, the flagship respiratory brand for asthma and allergic rhinitis, faced generic competition that press reports in the first half of 2026 identified as a burden on the company's respiratory-dependent structure. Lidomex in dermatology and Guard in gastrointestinal care support sales outside respiratory products.

Sales depend on prescriptions through clinics and hospitals and over-the-counter sales through pharmacies, so the scale of face-to-face sales activity feeds directly into revenue. The company is pursuing orthopedic, internal medicine and urology drugs to broaden its portfolio.

Its pipeline includes one new drug and two improved new drugs, and the most advanced, SA-16002, aimed at easing cough and phlegm, is in Phase 3. In March 2026, a charter amendment added raw pharmaceutical manufacturing and sales to its business purposes, which the company described as expansion of its business scope.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩15.1B-₩1.1B−7.4%
2025Q4₩20.8B₩2.7B12.8%
2026Q1₩17.6B₩2.1B11.8%
2026Q2₩18.8B₩1.9B10.0%
2026Q3₩17.4B₩600M3.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩81.7B₩18.3B₩11.9B22.3%6.6%12.5%
2023₩97.2B₩23.5B₩21.4B24.2%10.7%15.4%
2024₩95.6B₩24.5B₩22.1B25.6%10.0%13.1%
2025₩77.8B₩11B₩12.9B14.1%5.7%8.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a full-year basis, sales rose from KRW 81.7 billion in 2022 to KRW 97.2 billion in 2023, up 19.0% year on year, which was the largest year in the 2022-2025 period. Sales then fell 1.7% to KRW 95.6 billion in 2024 and 18.6% to KRW 77.8 billion in 2025, a decline for two consecutive years.

Operating profit grew from KRW 18.3 billion in 2022 to KRW 23.5 billion in 2023 (up 28.7%) and KRW 24.5 billion in 2024 (up 4.1%), making 2024 the largest year, before falling 55.1% to KRW 11 billion in 2025, the smallest year in the period.

The operating margin moved from 22.3% in 2022, 24.2% in 2023 and 25.6% in 2024 down to 14.1% in 2025, showing margin pressure alongside falling sales.

Profit attributable to controlling shareholders rose from KRW 11.9 billion in 2022 to KRW 21.4 billion in 2023 (up 79.4%) and KRW 22.1 billion in 2024 (up 3.3%), then fell 41.4% to KRW 12.9 billion in 2025.

Because all of year-end 2025 equity belonged to controlling shareholders, net income including non-controlling interests was the same KRW 12.9 billion.

Operating cash flow fell from KRW 25.2 billion in 2024 to KRW 10.7 billion in 2025, and the debt ratio rose from 12.5% in 2022 to 15.4% in 2023 before dropping to 8.3% in 2025. The quarterly pattern shows a clear turn.

In the third quarter of 2025, sales were KRW 15.1 billion with an operating loss of KRW 1.12 billion and a net loss attributable to controlling shareholders of KRW 54.06 million.

In the fourth quarter of 2025, sales rose 37.4% quarter on quarter to KRW 20.8 billion and the company returned to operating profit of KRW 2.65 billion.

Sales then came in at KRW 17.6 billion in the first quarter of 2026 (down 15.1% quarter on quarter), KRW 18.8 billion in the second quarter (up 6.5%) and KRW 17.4 billion in the third quarter (down 7.4%).

Operating profit declined for three consecutive quarters, from KRW 2.08 billion in the first quarter of 2026 to KRW 1.87 billion in the second and KRW 610 million in the third.

In the third quarter of 2026, sales were up 15.0% year on year, but operating profit fell 67.3% quarter on quarter and was only KRW 610 million.

Profit attributable to controlling shareholders peaked at KRW 4.35 billion in the second quarter of 2026 before falling to KRW 1.47 billion in the third quarter, and the last four quarters total KRW 12.1 billion.

05

Industry analysis

The most direct variable in the market Sam-A Pharm operates in is the flow of respiratory patients. A report explaining the first-quarter 2026 results cited a decline in respiratory patients as a reason for weaker sales.

At the same time, press reports said generic competition for Citus has intensified, pressuring both the price and share of the flagship product. Some commentary also warns that a drug pricing revision could add further price pressure.

Respiratory products have relatively stable demand and high volumes that can support economies of scale, but once price competition begins, the same structure becomes a burden on defending sales.

In this environment, small and mid-sized pharmaceutical companies are diversifying into new drugs and improved new drugs, and Sam-A Pharm is following that path.

Compared with listed peers such as Hanmi Pharm and Yuhan, which cover several therapeutic areas, Sam-A Pharm's pipeline of one new drug and two improved new drugs keeps its sales mix centered on respiratory products.

Non-respiratory lines such as gastrointestinal and dermatology remain small, which limits their role as an alternative source of revenue.

06

Outlook

The direction the company has officially stated is its corporate value enhancement plan, disclosed on March 27, 2026.

The plan targets better profitability through cost reduction and productivity gains, a stronger growth base through R&D and product competitiveness, and a shareholder return policy that reflects operating results and financial condition. The publicly summarized plan does not include numerical sales or profit targets.

The most advanced pipeline asset, SA-16002, is an improved new drug aimed at easing cough and phlegm, is in Phase 3, and the company plans to seek product approval after the trial is completed.

The candidate is described as working through mucus-dissolving and bronchial-spasm-suppressing actions to treat cough and phlegm from acute upper respiratory infections or bronchitis.

Press reports expect that, if commercialized, it could create synergy with the sales base the company has built in the respiratory market. SA-15001, an improved new drug for reflux esophagitis and gastroduodenal ulcers, is still in formulation research and is expected to enter clinical trials after that stage.

This fits the strategy of expanding into non-respiratory areas. The addition of raw pharmaceutical manufacturing to the business purposes is read as widening the company's scope of business. The next checkpoints are the Phase 3 results and filing timing for SA-16002 and the company's ability to defend Citus sales. The 2026 annual report will also show how far the operating margin recovers from 14.1% in 2025.

07

Valuation

PER
6.5×
PBR
0.3×
ROE
5.3%
EPS
₩1,977
BPS
₩37,634
Dividend per share
₩800

The current share price multiples sit at a low level relative to recent earnings. However, what the multiples mean depends on whether the earnings base, the denominator, recovers. The year-end earnings multiple was higher in 2025 than in 2023 and 2024, reflecting the decline in earnings over the same period.

The price-to-book multiple was lower than at the end of 2023, and because all of the KRW 228.1 billion in year-end 2025 equity belonged to controlling shareholders, the share price relative to book value is straightforward to read.

On payouts, the 2025 payout ratio was 40.15%, and the company disclosed that it qualifies as a high-dividend company under the Restriction of Special Taxation Act.

Based on the last four quarters' total of KRW 12.1 billion in profit attributable to controlling shareholders, earnings capacity depends on how quarterly results develop after the fourth quarter of 2025.

A low multiple relative to book value is a fact about comparison with asset value, and whether earnings keep declining changes what the same multiple means. To compare against industry averages or a historical band, the share price and earnings must be matched to the same dates.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Respiratory sales network and improved-drug pipeline

The company has maintained the sales base it built in respiratory products, and the improved new drug SA-16002 is in Phase 3. Press reports said that if commercialized, the candidate could create synergy with the existing respiratory sales network.

Two improved new drugs and one new drug under development give room to broaden revenue sources. Until trial results and approval arrive, however, this remains a possibility.

Signs of quarterly profit recovery

Operating profit returned to KRW 2.65 billion in the fourth quarter of 2025 after a loss in the third quarter. Profit attributable to controlling shareholders rose 95.2% quarter on quarter to KRW 4.35 billion in the second quarter of 2026.

Third-quarter 2026 sales of KRW 17.4 billion were up 15.0% year on year, showing that the top line grew in one quarter. The last four quarters total KRW 12.1 billion in profit attributable to controlling shareholders.

Balance sheet capacity and shareholder returns

Total liabilities at the end of 2025 were KRW 18.9 billion and the debt ratio was 8.3%, a relatively light debt burden. In its March 2026 corporate value enhancement plan, the company stated a goal of continuous shareholder returns. The 2025 payout ratio was 40.15%, and all KRW 228.1 billion of equity belongs to controlling shareholders.

09

Bear factors

Respiratory dependence and generic price pressure

Respiratory products made up 65.4% of sales in the first-quarter 2026 quarterly report, well over half. Press reports say generic competition for the flagship Citus has intensified, and commentary warns that a drug pricing revision could add price pressure. A decline in respiratory patients was also cited as a reason for weaker first-quarter 2026 results.

Falling operating profit and margin compression

Operating profit fell 55.1% to KRW 11 billion in 2025, and the operating margin dropped from 25.6% in 2024 to 14.1%. Operating profit declined for three consecutive quarters after the first quarter of 2026, from KRW 2.08 billion to KRW 1.87 billion and then KRW 610 million. Third-quarter 2026 sales rose year on year, but operating profit was only KRW 610 million.

Shrinking sales and a long pipeline timeline

Sales peaked at KRW 97.2 billion in 2023 and fell for two consecutive years in 2024 and 2025, down 18.6% to KRW 77.8 billion in 2025. Apart from one asset in Phase 3, the pipeline is at formulation research, so time is needed before it contributes to earnings. Until development results arrive, respiratory products will continue to carry the sales base.

10

Risk factors

Sales concentration and seasonality

Sales are concentrated in Citus and other respiratory products, so competition or prescription shifts in one product can move overall results. Analysts note that respiratory products show earnings volatility linked to seasonal factors. Sales fell 15.1% quarter on quarter in the first quarter of 2026.

Pipeline development and approval risk

If the Phase 3 results or product approval for SA-16002 fall short, securing a new revenue source will be delayed. SA-15001 is still at formulation research, so more time is needed before clinical entry. Development costs and staffing burdens could also weigh on operating profit.

Governance and management concentration

Representative director Heo Jun has been reported as a third-generation owner, and he was re-elected as an inside director at the March 2026 annual general meeting. After the election, one of the three board members is an outside director, a 33.3% outside-director ratio.

Because management is concentrated among inside directors and one family line, checks on decision-making may be limited.

11

What to watch next

  1. January to February 2027

    Whether full-year 2026 preliminary results are disclosed in the same window. Last year's preliminary annual results came out in late February 2026, and how far the operating margin recovers from 14.1% in 2025 is the point to check.

  2. End of March 2027

    Filing of the 2026 annual report, the next periodic report. Full-year sales, operating profit, profit attributable to controlling shareholders, debt ratio and operating cash flow will be fixed as disclosed results.

  3. End of March 2027 (annual general meeting)

    Approval of the year-end 2026 dividend and board elections. Last year's dividend was approved as a cash dividend, and this is the point to check the payout ratio and high-dividend status.

  4. Mid-May 2027

    The first-quarter 2027 quarterly report. It will show how the respiratory share, 65.4% in the first quarter of 2026, changes after generic competition for Citus.

  5. After 2027 (timing not yet set)

    Phase 3 results and product approval filing for the improved new drug SA-16002. Once the company discloses a timeline, this becomes the key test of whether a new revenue source can be secured.

12

Overall view

Sam-A Pharm is facing generic competition for Citus and a decline in profitability since 2025, in a structure where respiratory products account for more than 65% of sales.

On a disclosed basis, sales fell from KRW 97.2 billion in 2023 to KRW 77.8 billion in 2025, and the operating margin dropped from 25.6% in 2024 to 14.1% in 2025.

After returning to profit in the fourth quarter of 2025, quarterly sales have stayed between KRW 17.4 billion and KRW 18.8 billion, yet operating profit fell to KRW 610 million in the third quarter of 2026.

On the balance sheet, all KRW 228.1 billion of year-end 2025 equity belongs to controlling shareholders and the debt ratio is a low 8.3%. Shareholder returns are reflected in the March 2026 corporate value enhancement plan and a 2025 payout ratio of 40.15%.

Bullish factors include balance-sheet capacity, shareholder returns and the Phase 3 progress of SA-16002, while bearish factors include respiratory concentration, generic price pressure and continued profit decline.

The balance between these factors will depend largely on how far the operating margin recovers in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.fnguide.com
  2. dailypharm.com
  3. saramin.co.kr
  4. comp.wisereport.co.kr
  5. moneypie.net
  6. newsthevoice.com
  7. kind.krx.co.kr
  8. pharmnews.com
  9. yakup.com
  10. m.news.nate.com
  11. m.news.nate.com
  12. thebionews.net
  13. markets.hankyung.com
  14. m.dailypharm.com
  15. dart.fss.or.kr
  16. seoul.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis